Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
HnRNP-F promotes cell proliferation by regulating TPX2 in bladder cancer.
Li F
,
Su M
,
Zhao H
,
Xie W
,
Cao S
,
Xu Y
,
Chen W
,
Wang L
,
Hou L
,
Tan W
.
???displayArticle.abstract???
Heterogeneous nuclear ribonucleoprotein F (hnRNP-F) is crucial for gene expression and signal transduction as a tumor-promoting molecule with the ability to promote cell proliferation in various cancers. However, the role and mechanism of hnRNP-F in bladder cancer (BC) remain unclear. Therefore, we investigated the effect of hnRNP-F on the proliferation of BC cells and the potential mechanism. In this study, hnRNP-F was found to be upregulated in BC tissues and cells by western blotting. The knockdown of hnRNP-F could inhibit proliferation and delay cell cycle progression in EJ and UMUC-3 cells. Mechanistically, hnRNP-F was shown to bind to Targeting protein for Xenopus kinesin-like protein 2 (TPX2) by mass spectrometry and coimmunoprecipitation. Furthermore, Pearson correlation analysis showed that the expression of hnRNP-F was positively associated with that of TPX2 in BC tissues (P<0.001, r=0.8180). Notably, TPX2 was correspondingly markedly decreased in cells upon hnRNP-F knockdown. In addition, the decrease in TPX2 after hnRNP-F knockdown further decreased cyclin D1 protein expression and evoked p21 protein expression, eventually resulting in cell cycle arrest and proliferation inhibition in BC cells. Moreover, the overexpression of TPX2 protein was found to reverse the effect of hnRNP-F knockdown on the cell cycle and cell proliferation in BC cells. In conclusion, these findings suggest that hnRNP-F could promote cell proliferation and drive cell cycle progression by regulating TPX2 in BC, which may serve as a potential target for the treatment of BC patients.
Boukakis,
Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues.
2010, Pubmed
Boukakis,
Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues.
2010,
Pubmed
Chao,
Mst1 regulates glioma cell proliferation via the AKT/mTOR signaling pathway.
2015,
Pubmed
Chen,
Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer.
2017,
Pubmed
Chen,
MicroRNA-1294 inhibits the proliferation and enhances the chemosensitivity of glioma to temozolomide via the direct targeting of TPX2.
2018,
Pubmed
,
Xenbase
Cui,
Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma.
2010,
Pubmed
Geuens,
The hnRNP family: insights into their role in health and disease.
2016,
Pubmed
Goh,
Involvement of heterogeneous ribonucleoprotein F in the regulation of cell proliferation via the mammalian target of rapamycin/S6 kinase 2 pathway.
2010,
Pubmed
Gruss,
Chromosome-induced microtubule assembly mediated by TPX2 is required for spindle formation in HeLa cells.
2002,
Pubmed
,
Xenbase
Han,
Functional diversity of the hnRNPs: past, present and perspectives.
2010,
Pubmed
Heidebrecht,
p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M.
1997,
Pubmed
Holzapfel,
Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load.
2017,
Pubmed
Honoré,
Heterogeneous nuclear ribonucleoproteins F and H/H' show differential expression in normal and selected cancer tissues.
2004,
Pubmed
Hou,
Association between dietary patterns and coronary heart disease: a meta-analysis of prospective cohort studies.
2015,
Pubmed
Konno,
Expression of survivin and Bcl-2 in the normal human endometrium.
2000,
Pubmed
Kufer,
Human TPX2 is required for targeting Aurora-A kinase to the spindle.
2002,
Pubmed
,
Xenbase
Lei,
The decrease of cyclin B2 expression inhibits invasion and metastasis of bladder cancer.
2016,
Pubmed
Li,
A greater number of dissected lymph nodes is associated with more favorable outcomes in bladder cancer treated by radical cystectomy: a meta-analysis.
2016,
Pubmed
Li,
Identification of urinary Gc-globulin as a novel biomarker for bladder cancer by two-dimensional fluorescent differential gel electrophoresis (2D-DIGE).
2012,
Pubmed
Li,
The increased excretion of urinary orosomucoid 1 as a useful biomarker for bladder cancer.
2016,
Pubmed
Li,
HnRNP-F regulates EMT in bladder cancer by mediating the stabilization of Snail1 mRNA by binding to its 3' UTR.
2019,
Pubmed
Li,
Egg consumption and risk of bladder cancer: a meta-analysis.
2013,
Pubmed
Luo,
Characteristics of bladder transitional cell carcinoma with E-cadherin and N-cadherin double-negative expression.
2016,
Pubmed
Lv,
HnRNP-L mediates bladder cancer progression by inhibiting apoptotic signaling and enhancing MAPK signaling pathways.
2017,
Pubmed
Pan,
Targeted TPX2 increases chromosome missegregation and suppresses tumor cell growth in human prostate cancer.
2017,
Pubmed
Qie,
Cyclin D1, cancer progression, and opportunities in cancer treatment.
2016,
Pubmed
Rodriguez-Aguayo,
PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.
2019,
Pubmed
Song,
Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
2018,
Pubmed
Wen,
miR-424 coordinates multilayered regulation of cell cycle progression to promote esophageal squamous cell carcinoma cell proliferation.
2018,
Pubmed
Xu,
ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.
2018,
Pubmed
Yamazaki,
TCF3 alternative splicing controlled by hnRNP H/F regulates E-cadherin expression and hESC pluripotency.
2018,
Pubmed
Yan,
Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma.
2013,
Pubmed
